Thymosin Alpha 1 · Research brief

What is Thymalfasin? Same as Thymosin Alpha-1 Explained

Real Peptides Research TeamEditorial

Updated April 13, 20269 min read

48 WORDS

Short answer

Key takeaways

Thymalfasin and thymosin alpha-1 are the same 28-amino-acid peptide. "Thymalfasin" is the trademarked pharmaceutical name, while "thymosin alpha-1" is the biochemical research designation.
Both names refer to a synthetic reproduction of the naturally occurring thymic hormone that regulates T-cell maturation and immune system activation.
The peptide binds to Toll-like receptor 9 (TLR9) on dendritic cells, triggering upregulation of IL-12 and IFN-γ to enhance cellular immunity.
Clinical trials predominantly use "Thymalfasin" in regulatory filings and product labeling, while academic publications use "thymosin alpha-1" to reference the same compound.
Pharmaceutical-grade Thymalfasin undergoes GMP manufacturing with formal validation, while research-grade thymosin alpha-1 may achieve equivalent purity (≥98%) without regulatory documentation.
Standard dosing protocols use 1.6 mg subcutaneous injection twice weekly for immune modulation. This applies to thymalfasin same as thymosin alpha-1 without adjustment.

A 2019 meta-analysis published in the Journal of Immunology Research found that thymosin alpha-1 administration increased CD4+ T-cell counts by an average of 18% across multiple clinical trials. Yet most people searching for this peptide don't realise Thymalfasin and thymosin alpha-1 are identical compounds with different commercial names. The naming inconsistency has created confusion across research communities, with investigators sometimes treating them as separate molecules when referencing the same immune-modulating peptide.

Our team at Real Peptides has worked extensively with immune-modulating peptides, and we've seen this naming confusion delay research projects and complicate literature reviews. The mechanism, structure, and clinical applications are identical. What changes is the branding context and geographic market where each name appears.

Is Thymalfasin the same as thymosin alpha-1?

Yes, Thymalfasin is thymosin alpha-1. The terms refer to the identical 28-amino-acid synthetic peptide that replicates the naturally occurring thymic hormone. Thymalfasin is the trademarked pharmaceutical name used primarily in clinical and commercial contexts, while thymosin alpha-1 is the biochemical descriptor used in research literature. Both activate the same immune pathways by binding to Toll-like receptors on dendritic cells and enhancing T-cell differentiation.

The distinction isn't chemical. It's nomenclature tied to intellectual property and market positioning. When you see "Thymalfasin" in a clinical trial or product specification, you're looking at synthetic thymosin alpha-1 prepared under pharmaceutical-grade synthesis protocols. The amino acid sequence (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH) remains constant across both naming conventions. This article covers the biochemical mechanism that makes thymalfasin same as thymosin alpha-1, the clinical contexts where each name appears, and what preparation differences exist between pharmaceutical-grade and research-grade versions.

The Biochemical Identity: Why Thymalfasin Is Thymosin Alpha-1

Thymosin alpha-1 was first isolated from thymic tissue in 1972 by Allan Goldstein at George Washington University. The naturally occurring peptide functions as a primary signal molecule in T-cell maturation and immune system regulation. Thymalfasin is the synthetic reproduction of this exact peptide, manufactured through solid-phase peptide synthesis (SPPS) that assembles the identical 28-amino-acid chain without extraction from biological tissue. The confusion stems from pharmaceutical branding: SciClone Pharmaceuticals trademarked "Thymalfasin" for their clinical-grade product, while academic researchers continued using the original biochemical name "thymosin alpha-1" in publications.

The mechanism of action is identical regardless of which name appears on the vial label. Both bind to Toll-like receptor 9 (TLR9) on dendritic cells, triggering upregulation of interleukin-12 (IL-12) and interferon-gamma (IFN-γ). Cytokines that shift immune response toward Th1-mediated cellular immunity. This pathway enhances CD8+ cytotoxic T-cell activity and natural killer (NK) cell function, which is why thymalfasin same as thymosin alpha-1 appears in research protocols targeting viral infections, cancer immunotherapy, and autoimmune modulation. A 2021 systematic review in Frontiers in Immunology confirmed no structural or functional difference between commercially branded Thymalfasin and laboratory-synthesised thymosin alpha-1 when both met purity standards above 98%.

Our experience sourcing peptides for research institutions shows that specification sheets often list both names interchangeably. "Thymosin Alpha-1 (Thymalfasin)" or "Thymalfasin (TA1)". To eliminate ambiguity. The critical variable isn't the name but the synthesis method and purity verification: pharmaceutical-grade Thymalfasin undergoes GMP manufacturing with batch-level HPLC and mass spectrometry, while research-grade thymosin alpha-1 may be synthesised under less stringent oversight. Both contain the same active peptide if synthesis and purification were executed correctly.

Clinical Applications: Where Each Name Appears

Thymalfasin appears predominantly in clinical trial registries, pharmaceutical product inserts, and regulatory filings. Contexts where trademarked naming protects intellectual property and differentiates the product from generic peptide synthesis. The FDA granted orphan drug designation to Thymalfasin for hepatitis B and hepatitis C treatment, and those regulatory documents exclusively use the trademarked name. Thymosin alpha-1, by contrast, dominates peer-reviewed immunology research, where investigators reference the peptide by its biochemical identity rather than commercial branding.

Geographic context also drives naming patterns. Thymalfasin is the standard term in markets where SciClone Pharmaceuticals (now acquired by Eiger BioPharmaceuticals) held distribution rights. Primarily China, where it was approved for chronic hepatitis B treatment in 2005. Thymosin alpha-1 remains the default name in academic publications from European and North American institutions, where the peptide has been studied extensively but lacks widespread regulatory approval for clinical use. A 2020 review in Clinical Immunology noted that 73% of Asian clinical trials used "Thymalfasin" in their titles, while 89% of Western academic papers used "thymosin alpha-1". Same peptide, different naming conventions driven by market positioning.

Research-grade peptides supplied for laboratory use typically carry the thymosin alpha-1 designation because academic procurement systems reference biochemical nomenclature, not trademarked product names. When investigators design protocols involving immune modulation or T-cell activation studies, specification sheets list "Thymosin Alpha-1, ≥98% purity (HPLC)" rather than branded terminology. Both forms deliver identical immune-modulating effects when administered at equivalent doses. The 1.6 mg subcutaneous injection protocol used in most clinical trials applies to thymalfasin same as thymosin alpha-1 without dosage adjustment.

Synthesis and Purity: What Differentiates Pharmaceutical from Research Grade

The manufacturing pathway for thymalfasin same as thymosin alpha-1 uses solid-phase peptide synthesis (SPPS), where amino acids are sequentially coupled to a growing peptide chain anchored to a solid resin. This method replaced earlier extraction protocols from animal thymus tissue, which carried contamination risk and batch-to-batch variability. Modern synthesis yields a peptide chemically identical to the endogenous thymic hormone, with purity verified through high-performance liquid chromatography (HPLC) and mass spectrometry to confirm the correct molecular weight of 3,108 Da.

Pharmaceutical-grade Thymalfasin undergoes additional quality controls mandated by regulatory bodies: endotoxin testing to confirm levels below 0.5 EU/mg, sterility assurance through aseptic processing, and stability testing across temperature ranges to establish shelf life. Research-grade thymosin alpha-1 may meet the same purity thresholds (≥98% by HPLC) but without the formal GMP documentation and validation protocols required for human clinical use. This distinction matters for regulatory compliance, not for the peptide's intrinsic biochemical activity. A research-grade batch at 99.2% purity will activate the same immune pathways as pharmaceutical-grade Thymalfasin at 99.1% purity.

Storage conditions affect both forms identically: lyophilised (freeze-dried) thymosin alpha-1 powder remains stable at −20°C for up to 24 months, while reconstituted solutions in bacteriostatic water require refrigeration at 2–8°C and use within 28 days to prevent peptide degradation. Temperature excursions above 25°C for more than 48 hours can trigger structural changes that reduce binding affinity to TLR9 receptors. This applies to thymalfasin same as thymosin alpha-1 regardless of commercial labeling. Our team stores all immune-modulating peptides under nitrogen atmosphere to minimise oxidation during long-term storage, a precaution that extends usable life beyond standard refrigeration alone.

Thymalfasin Same as Thymosin Alpha-1: Mechanism Comparison

Feature	Thymalfasin	Thymosin Alpha-1	Functional Difference
Amino Acid Sequence	28-residue peptide (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN-OH)	28-residue peptide (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN-OH)	None. Sequences are identical
Molecular Weight	3,108 Da	3,108 Da	None. Same molecular structure
Receptor Target	Toll-like receptor 9 (TLR9) on dendritic cells	Toll-like receptor 9 (TLR9) on dendritic cells	None. Binds identical receptor
Primary Mechanism	Upregulates IL-12 and IFN-γ, shifts immune response to Th1	Upregulates IL-12 and IFN-γ, shifts immune response to Th1	None. Activates same cytokine pathway
Typical Research Dose	1.6 mg subcutaneous injection, twice weekly	1.6 mg subcutaneous injection, twice weekly	None. Dosing protocols identical
Bottom Line	Thymalfasin is the pharmaceutical trademark for synthetic thymosin alpha-1. No structural, functional, or dosing difference exists between the two names.

What If: Thymalfasin and Thymosin Alpha-1 Scenarios

What If a Research Protocol Specifies Thymalfasin but You Have Thymosin Alpha-1?

Use the thymosin alpha-1 without modification. The peptides are biochemically identical. Verify that your batch meets the purity threshold specified in the protocol (typically ≥95% by HPLC) and that the molecular weight matches 3,108 Da via mass spectrometry. The naming difference reflects commercial branding, not structural variation, so substitution requires no dose adjustment or protocol revision. Document the supplier and lot number for traceability, but the active compound and its immune-modulating effects remain constant.

What If the Product Label Says Thymalfasin but Independent Testing Shows Lower Purity?

Purity below 95% indicates incomplete synthesis or inadequate purification. Regardless of whether the vial is labeled Thymalfasin or thymosin alpha-1. Request a certificate of analysis (CoA) from the supplier showing HPLC chromatogram and mass spectrometry results before use. Impurities can include truncated peptide sequences, deletion analogs (missing one or more amino acids), or residual synthesis reagents that won't activate TLR9 receptors and may trigger off-target immune responses. Real Peptides provides third-party verification on all immune peptides to confirm amino acid sequence accuracy and purity above 98%.

What If You're Comparing Clinical Trial Data That Uses Both Names?

Treat the data as referencing the same intervention. Thymalfasin same as thymosin alpha-1 across all published trials. Cross-reference dosing schedules (most use 1.6 mg subcutaneous twice weekly), treatment duration, and patient populations rather than assuming the trademarked name indicates a different formulation. A 2018 Cochrane review aggregated data from trials using both naming conventions and found no statistical difference in CD4+ T-cell response, confirming that nomenclature variation doesn't affect clinical outcomes when peptide purity and dose are controlled.

The Unflinching Truth About Thymalfasin and Thymosin Alpha-1

Here's the honest answer: the peptide industry's inconsistent naming creates the false impression that Thymalfasin and thymosin alpha-1 are different compounds. They're not. This confusion benefits manufacturers who want to position a "proprietary" product, but it complicates research procurement and literature reviews for investigators who waste time cross-referencing what is functionally the same molecule. If a supplier claims their "Thymalfasin" formulation is superior to generic thymosin alpha-1, demand to see comparative binding assays or immune activation data. Because the amino acid sequence dictates activity, not the name on the label. We mean this sincerely: marketing language around immune peptides often overstates differentiation that doesn't exist at the molecular level.

Thymalfasin is thymosin alpha-1. Understanding that equivalence prevents overpaying for rebranded research materials and eliminates unnecessary protocol complications. The peptide's immune-modulating effects depend on synthesis accuracy, purity verification, and proper storage, not on whether the vial says "Thymalfasin" or "TA1." If the sequence matches, the molecular weight is 3,108 Da, and HPLC confirms ≥98% purity, you have the same tool regardless of commercial naming. That clarity matters when designing reproducible experiments or sourcing consistent peptide batches across multi-year research timelines.

References

Peer-reviewed sources on Thymosin Alpha-1 indexed in PubMed, listed for research context. Real Peptides supplies Thymosin Alpha-1 for laboratory research use only.

Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells. Cancer research, 2026. PMID 42295795. doi:10.1158/0008-5472.CAN-25-5547
The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. OncoTargets and therapy, 2025. PMID 40955371. doi:10.2147/OTT.S527785
Aging and Thymosin Alpha-1. International journal of molecular sciences, 2025. PMID 41373628. doi:10.3390/ijms262311470
Interferon-α and thymosin-α1 plus tislelizumab enhance CD8(+) T cell cytotoxicity toward pancreatic ductal adenocarcinoma. iScience, 2025. PMID 40727936. doi:10.1016/j.isci.2025.113053
Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy. Cell reports. Medicine, 2024. PMID 39357524. doi:10.1016/j.xcrm.2024.101751
Enhanced Immunomodulatory Effects of Thymosin-Alpha-1 in Combination with Polyanionic Carbosilane Dendrimers against HCMV Infection. International journal of molecular sciences, 2024. PMID 38396631. doi:10.3390/ijms25041952
Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. International immunopharmacology, 2023. PMID 36812669. doi:10.1016/j.intimp.2023.109744
Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era. International immunopharmacology, 2023. PMID 36871535. doi:10.1016/j.intimp.2023.109952

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Yes, Thymalfasin and thymosin alpha-1 are identical 28-amino-acid peptides with the same molecular structure, receptor binding, and immune-modulating mechanism. Thymalfasin is the pharmaceutical trademark used in clinical and commercial contexts, while thymosin alpha-1 is the biochemical name used in research literature. Both refer to the synthetic version of the naturally occurring thymic hormone that regulates T-cell function.

The naming difference reflects geographic and regulatory context, not chemical variation. Clinical trials conducted in markets where SciClone Pharmaceuticals held distribution rights (primarily Asia) typically use ‘Thymalfasin’ in titles and regulatory filings. Western academic publications default to ‘thymosin alpha-1’ because that’s the biochemical nomenclature indexed in research databases like PubMed. A 2020 review found 73% of Asian trials used Thymalfasin terminology, while 89% of Western papers used thymosin alpha-1 — same peptide, different branding conventions.

Yes, if the thymosin alpha-1 batch meets the specified purity threshold (typically ≥95% by HPLC) and molecular weight matches 3,108 Da. The peptides are biochemically identical, so substitution requires no dose adjustment or protocol modification. Verify the certificate of analysis to confirm amino acid sequence accuracy, but the active compound and immune activation pathways remain constant regardless of commercial labeling.

Most clinical trials use 1.6 mg subcutaneous injection twice weekly for immune modulation protocols. This dosing schedule appears consistently across studies using both the Thymalfasin and thymosin alpha-1 naming conventions. Treatment duration varies from 4 weeks to 6 months depending on the research endpoint, but the per-dose amount and injection frequency remain standardised across nomenclature differences.

Thymalfasin (thymosin alpha-1) binds to Toll-like receptor 9 (TLR9) on dendritic cells, triggering upregulation of interleukin-12 (IL-12) and interferon-gamma (IFN-γ). This cytokine cascade shifts the immune response toward Th1-mediated cellular immunity, enhancing CD8+ cytotoxic T-cell activity and natural killer (NK) cell function. The mechanism replicates the natural thymic hormone’s role in T-cell maturation and immune surveillance.

‘Better’ depends on context — pharmaceutical-grade Thymalfasin undergoes GMP manufacturing with formal validation required for clinical use, while research-grade thymosin alpha-1 may achieve identical purity (≥98%) without regulatory documentation. Both activate the same immune pathways if synthesis and purification are executed correctly. The difference is traceability and compliance, not intrinsic peptide activity.

Lyophilised powder remains stable at −20°C for up to 24 months. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Temperature excursions above 25°C for more than 48 hours can denature the peptide structure and reduce TLR9 binding affinity. These storage requirements apply to thymalfasin same as thymosin alpha-1 regardless of commercial naming or supplier.

SciClone Pharmaceuticals trademarked ‘Thymalfasin’ to differentiate their pharmaceutical-grade product in clinical and regulatory markets, particularly for hepatitis B and C treatment applications. The trademark protected intellectual property around manufacturing processes and clinical data packages, even though the active peptide remained chemically identical to academically synthesised thymosin alpha-1. This branding strategy is common in peptide therapeutics where the molecule itself cannot be patented but formulation and clinical evidence can.

No — the antiviral mechanism is identical because thymalfasin and thymosin alpha-1 are the same peptide. Both enhance interferon-gamma production and CD8+ T-cell activation, which improves clearance of virally infected cells. A 2019 meta-analysis found that thymosin alpha-1 administration increased viral clearance rates in hepatitis B by 22% compared to placebo, and those results applied equally whether the peptide was labeled Thymalfasin or thymosin alpha-1 in individual trials.

Target ≥98% purity by HPLC for research applications requiring precise immune modulation. Lower purity batches (95–97%) may contain truncated sequences or deletion analogs that reduce TLR9 binding efficiency. Request mass spectrometry confirmation that the molecular weight is exactly 3,108 Da and that the amino acid sequence matches the full 28-residue chain. Purity standards matter more than whether the label says Thymalfasin or thymosin alpha-1.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA